Bris­tol My­ers, Ab­b­Vie drugs shake up first-line pre­scrib­ing among gas­troen­terol­o­gists — re­port

Bris­tol My­ers Squibb and Ab­b­Vie are chang­ing up the in­flam­ma­to­ry bow­el dis­ease (IBD) mar­ket with gas­troen­terol­o­gists, thanks to new­er-to-mar­ket drugs Zeposia and Skyrizi, re­spec­tive­ly. The two drugs have made big gains since 2021 in first-line pre­scrip­tions, ac­cord­ing to Spher­ix Glob­al In­sights’ lat­est re­al world track­ing re­port.

Bris­tol My­ers’ first-in-class S1P Zeposia has land­ed par­tic­u­lar­ly strong, pick­ing up “a size­able por­tion of first line pa­tients” in ul­cer­a­tive col­i­tis (UC), Spher­ix’s analy­sis found.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER